| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.025 | 0.8 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.8 |